Cost-Effective HIV PrEP: CAB-LA Transforms Prevention

Summary

Cabotegravir long-acting (CAB-LA) delivers a cost-effective HIV PrEP solution. It reduces infections and supports the Ending the HIV Epidemic (EHE) initiative. This review examines CAB-LA’s published economic and health benefits. It guides pharmaceutical executives and health policymakers to optimize PrEP strategies for diverse populations.

Why CAB-LA Excels in HIV Prevention

HIV remains a major U.S. public health issue. In 2019, nearly 37,000 new diagnoses occurred, disproportionately affecting underserved groups. Only 23% of eligible individuals use oral PrEP due to adherence challenges. Approved in 2021, CAB-LA outperforms oral PrEP. HPTN 083 and 084 trials show 66% and 88% reductions in HIV-1 acquisition for MSM/TGW and cisgender women, respectively. CAB-LA’s injectable format addresses adherence barriers, making it a game-changer.

How Cost-Effective Is CAB-LA?

CAB-LA proves cost-effective compared to generic oral FTC/TDF. It prevents 4.5 more HIV-1 infections per 100 PrEP users. This saves 0.2 quality-adjusted life-years (QALYs) per person. CAB-LA’s PrEP costs are higher ($54,631 vs. $4,028). Yet, it cuts HIV management costs by $42,517, adding $9,476 per person. The incremental cost-effectiveness ratio (ICER) is $46,843 per QALY, below the $100,000 threshold. Sensitivity analyses confirm stability. CAB-LA is cost-effective in 85% of simulations. It is cost-saving for cisgender women and African American/Black MSM, aligning with EHE goals.

Capivasertib Cost-Effectiveness in Advanced Breast Cancer

April 18, 2025April 18, 2025 Rene Pretorius

💡What’s the strategy to bring capivasertib’s price within reach of breast cancer patients?

A recent study evaluates capivasertib, an AKT inhibitor, as a second-line treatment for advanced breast cancer, revealing that its costs significantly outweigh the added health benefits. The analysis indicates that to be cost-effective, a substantial reduction in its price is necessary.

Delve into the economic implications of this treatment and the pressing need for pricing reforms in healthcare.

#SyenzaNews #HealthEconomics #costeffectiveness #oncology

Reserve Antibiotics Benefits: G-BA Designates Meropenem/Vaborbactam as Critical Reserve Treatment

April 18, 2025 João L. Carapinha

🔍 What makes reserve antibiotics crucial in the fight against antimicrobial resistance?

The recent assessment of Meropenem/Vaborbactam by the G-BA highlights its vital role as a reserve antibiotic for severe gram-negative infections, ensuring effective treatment options when others fail. With tight regulations and stewardship in place, its designation underscores the importance of preserving these powerful tools in modern medicine.

Dive into the article to explore the implications for healthcare, economics, and patient safety.

#SyenzaNews #HealthcareInnovation #HealthEconomics

NICE Grants Conditional Robotic Surgery Approval to Enhance Patient Care and Address Health Inequities

April 17, 2025April 17, 2025 João L. Carapinha

🤖 Are you ready for the future of surgery?

The recent approval of 11 robotic surgery systems by NICE could improve patient care in the NHS, leading to faster recoveries and minimal invasiveness. With a focus on real-world evidence, this transformative step aims to improve health outcomes while addressing access and equity concerns.

Explore how this innovative approach will shape the landscape of surgical procedures in the coming years!

#SyenzaNews #HealthcareInnovation #MedicalDevices #MarketAccess